164 related articles for article (PubMed ID: 22844442)
1. Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.
Huang SP; Bao BY; Hour TC; Huang CY; Yu CC; Liu CC; Lee YC; Huang CN; Pao JB; Huang CH
PLoS One; 2012; 7(7):e41219. PubMed ID: 22844442
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.
Huang CN; Huang SP; Pao JB; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Pu YS; Hsieh CJ; Bao BY
Ann Oncol; 2012 Mar; 23(3):707-713. PubMed ID: 21652578
[TBL] [Abstract][Full Text] [Related]
4. Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy.
Bao BY; Pao JB; Huang CN; Pu YS; Chang TY; Lan YH; Lu TL; Lee HZ; Chen LM; Ting WC; Hsieh CJ; Huang SP
Int J Cancer; 2012 Feb; 130(4):876-84. PubMed ID: 21445969
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients.
Huang SP; Lin VC; Lee YC; Yu CC; Huang CY; Chang TY; Lee HZ; Juang SH; Lu TL; Bao BY
Eur J Cancer; 2013 Nov; 49(17):3729-37. PubMed ID: 23920401
[TBL] [Abstract][Full Text] [Related]
6. Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.
Lin VC; Huang CY; Lee YC; Yu CC; Chang TY; Lu TL; Huang SP; Bao BY
Arch Toxicol; 2014 Apr; 88(4):901-11. PubMed ID: 24448834
[TBL] [Abstract][Full Text] [Related]
7. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.
Lin DW; FitzGerald LM; Fu R; Kwon EM; Zheng SL; Kolb S; Wiklund F; Stattin P; Isaacs WB; Xu J; Ostrander EA; Feng Z; Grönberg H; Stanford JL
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1928-36. PubMed ID: 21846818
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.
Yu CC; Huang SP; Lee YC; Huang CY; Liu CC; Hour TC; Huang CN; You BJ; Chang TY; Huang CH; Bao BY
PLoS One; 2013; 8(1):e54627. PubMed ID: 23359804
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
11. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
[TBL] [Abstract][Full Text] [Related]
12. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
[TBL] [Abstract][Full Text] [Related]
13. Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Geng JH; Lin VC; Yu CC; Huang CY; Yin HL; Chang TY; Lu TL; Huang SP; Bao BY
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27898031
[TBL] [Abstract][Full Text] [Related]
14. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
15. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.
Shiota M; Tatarano S; Kamoto T; Matsuyama H; Sakai H; Igawa T; Kamba T; Fujimoto N; Sekine Y; Kimura H; Narita S; Terada N; Momozawa Y; Akamatsu S; Habuchi T; Yokomizo A; Naito S; Eto M
Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37079309
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.
de Souza MR; de Souza MF; de Nóbrega M; Cilião HL; Dos Reis MB; Fuganti PE; Cólus IMS
Mol Biol Rep; 2022 Sep; 49(9):9079-9087. PubMed ID: 35708863
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer.
Pao JB; Yang YP; Huang CN; Huang SP; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Huang CY; Bao BY
World J Urol; 2013 Apr; 31(2):281-7. PubMed ID: 22193519
[TBL] [Abstract][Full Text] [Related]
19. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
[TBL] [Abstract][Full Text] [Related]
20.
Huang SP; Chen LC; Chen YT; Lee CH; Huang CY; Yu CC; Lin VC; Lu TL; Bao BY
Cancer Genomics Proteomics; 2021; 18(3):325-334. PubMed ID: 33893085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
